Search results for "DoS"

showing 10 items of 7181 documents

Results of a dental care protocol for mentally handicapped patients set in a primary health care area in Spain

2007

Objective: Disabled people have the same right as other people to receive the health care they need, but they sometimes have difficulties to achieve it. In Castilla y Leon it has come into effect a law to guarantee Primary and Secondary Care coordination to provide dental treatment under sedation or anaesthesia to mentally disabled people who need it. Our aim is to evaluate the results of the implementation of such a law through a specific protocol in our health setting. Study design: Descriptive, made in a Health Area over a year, on mentally disabled people who were sent to hospital for treatment under anaesthesia after Primary Dental Care Units assessment. It has been studied the age, ge…

stomatognathic diseasesstomatognathic systempatient care planningUNESCO::CIENCIAS MÉDICASCuidados dentales en discapacitadosDental care for disabledevaluación de programasplanificación de cuidadosprogram evaluation:CIENCIAS MÉDICAS [UNESCO]
researchProduct

La comercialización de los tejidos de seda valencianos con América y sus dinámicas: una aproximación a través de la correspondencia de la Compañía de…

2022

Ribes Sáez, Francisco: La comercialización de los tejidos de seda valencianos con América y sus dinámicas: una aproximación a través de la correspondencia de la Compañía de Nuestra Señora de los Desamparados (1775-1786). . En: Estudis: Revista de historia moderna, 48 2022: 277-298

tejidos de sedaUNESCO::HISTORIAcorrespondencia:HISTORIA [UNESCO]valenciacomercio colonialhispanoamérica
researchProduct

Sezernierter Interleukin-2-Rezeptor als Aktivitätsparameter der Sarkoidose*

2008

Serum sIL-2-R levels were measured in 28 sarcoidosis patients at multiple time points before, during, and after therapy, with a mean follow-up time of 10.2 +/- 5.2 months, and the results compared with the clinical activity of the disease. Before therapy, 20 out of 24 episodes with active disease exhibited elevated levels of sIL-2-R (918 +/- 362 U/ml). In inactive disease after tapering off corticoid therapy the sIL-2-R levels were 453 +/- 274 U/ml. Disease activity under therapy also correlated with sIL-2-R serum levels. 23 out of 29 episodes with signs of activity under therapy had elevated sIL-2-R levels (808 +/- 409 U/ml). Only three of 28 patients in whom disease activity ceased after …

medicine.medical_specialtybusiness.industryGeneral MedicineDiseasemedicine.diseaseGastroenterologyfemale genital diseases and pregnancy complicationsDisease activityPulmonary sarcoidosisimmune system diseaseshemic and lymphatic diseasesInternal medicineActive diseaseMultiple timeMedicineSarcoidosisbusinessInactive diseaseReceptorDMW - Deutsche Medizinische Wochenschrift
researchProduct

In vitro fusion of phagosomes with different endocytic organelles from J774 macrophages.

1998

We describe novel biochemical and electron microscopy assays to investigate in vitro fusion of latex bead phagosomes with three different endocytic organelle fractions from J774 macrophages. After formation, early phagosomes fuse avidly with early and late endosomes and for a longer period of time with lysosomes, but they subsequently become fusion-incompetent. The fusion of early, but not late, phagosomes with all three endocytic fractions could be significantly stimulated by Rab5. In contrast to other cell types investigated, this Rab is uniquely enriched on both early and late endosomes in J774 macrophages. Moreover, exogenous Rab5 stimulates homotypic fusion between both sets of organel…

Cell typeEndosomeMacrophagesEndocytic cycleCell BiologyBiologyBiochemistryIn vitroEndocytosisCell biologyCell LineCell FusionMiceCricetinaePhagosomesOrganelleAnimalsHumansRabMolecular BiologyFusion mechanismPhagosomeThe Journal of biological chemistry
researchProduct

Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Enalapril

2018

Literature data relevant to the decision to allow a waiver of in vivo bioequivalence testing for the marketing authorization of immediate-release, solid oral dosage forms containing enalapril maleate are reviewed. Enalapril, a prodrug, is hydrolyzed by carboxylesterases to the active angiotensin-converting enzyme inhibitor enalaprilat. Enalapril as the maleate salt is shown to be highly soluble, but only 60%-70% of an orally administered dose of enalapril is absorbed from the gastrointestinal tract into the enterocytes. Consequently, enalapril maleate is a Biopharmaceutics Classification System class III substance. Because in situ conversion of the maleate salt to the sodium salt is sometim…

DrugEnalaprilatmedia_common.quotation_subjectAdministration OralPharmaceutical ScienceAngiotensin-Converting Enzyme InhibitorsBioequivalencePharmacology030226 pharmacology & pharmacyPermeabilityDosage form03 medical and health sciences0302 clinical medicineDrug StabilityEnalaprilmedicineHumansProdrugsEnalaprilmedia_commonChromatographyChemistryProdrugBiopharmaceutics Classification SystemIntestinal AbsorptionSolubilityTherapeutic EquivalencyEnalapril Maleate030220 oncology & carcinogenesisTabletsmedicine.drugJournal of Pharmaceutical Sciences
researchProduct

Effects of l-Carnitine in Patients with Autism Spectrum Disorders: Review of Clinical Studies

2019

Carnitine is an amino acid derivative, which plays several important roles in human physiology, in the central nervous system, and for mitochondrial metabolism, in particular. Altered carnitine metabolic routes have been associated with a subgroup of patients with autism spectrum disorders (ASD) and could add to the pathophysiology associated with these disorders. We review the current evidence about the clinical effects of carnitine administration in ASD in both non-syndromic forms and ASD associated with genetic disorders. Two randomized clinical trials and one open-label prospective trial suggest that carnitine administration could be useful for treating symptoms in non-syndromic ASD. Th…

medicine.medical_specialtyAutism Spectrum DisorderCentral nervous systemPharmaceutical ScienceReviewComorbidityAnalytical Chemistrylaw.inventionlcsh:QD241-44103 medical and health sciences0302 clinical medicineNeurodevelopmental disorderlcsh:Organic chemistryRandomized controlled triallawCarnitineInternal medicinemental disordersDrug DiscoveryIntellectual disabilitymedicineHumansgenetic disordersGenetic Predisposition to DiseaseCarnitinePhysical and Theoretical ChemistryRandomized Controlled Trials as Topic030304 developmental biology0303 health sciencesDose-Response Relationship Drugbusiness.industryOrganic Chemistryvitaminmedicine.diseaseneurodevelopmental disorderPathophysiologyClinical trialTreatment Outcomemedicine.anatomical_structureChemistry (miscellaneous)Molecular MedicineAutismnutritional supplementationbusinessmetabolism030217 neurology & neurosurgerymedicine.drugMolecules
researchProduct

Il neonato che “sa di sale”

2021

Pseudohypoaldosteronism type 1 (PHA1) is a rare genetic disease due to the peripheral resistance to aldosterone. Clinical spectrum with neonatal onset includes salt loss, hyponatremia, hypochloraemia, hyperkalaemia, metabolic acidosis and increased plasmatic levels of aldosterone. Two forms of the disease - renal and systemic – have been described, which are genetically distinct and with wide clinical expressivity. The most severe generalized PHA1 is caused by mutations in the genes encoding for the subunits of the epithelial sodium channels (ENaC). The paper reports the case of a newborn of the first pregnancy of healthy and consanguineous Sicilian parents, with a clinical and hormonal pic…

03 medical and health sciences0302 clinical medicinebusiness.industryPediatrics Perinatology and Child HealthMedicine030209 endocrinology & metabolismPseudohypoaldosteronism ENaC SCNN1A gene New splicing mutation Next generation sequencingbusiness030217 neurology & neurosurgery
researchProduct

New exclusion limits on scalar and pseudoscalar axionlike particles from light shining through a wall

2015

Physics beyond the Standard Model predicts the possible existence of new particles that can be searched at the low-energy frontier in the sub-eV range. The OSQAR photon regeneration experiment looks for ``light shining through a wall'' from the quantum oscillation of optical photons into ``weakly interacting sub-eV particles,'' such as axion or axionlike particles (ALPs) in a 9 T transverse magnetic field over a length of $2\ifmmode\times\else\texttimes\fi{}14.3\text{ }\text{ }\mathrm{m}$. In 2014, this experiment was run with an outstanding sensitivity, using an 18.5 W continuous wave laser emitting in the green at the single wavelength of 532 nm. No regenerated photons have been detected …

[PHYS]Physics [physics]PhysicsNuclear and High Energy PhysicsParticle physicsPhoton010308 nuclear & particles physicsPhysics beyond the Standard ModelScalar (mathematics)Scalar and Pseudoscalar Axion-like ParticlesPhoton RegenerationType (model theory)01 natural sciencesMassless particlePseudoscalarAxionQuantum mechanics0103 physical sciencesSensitivity (control systems)010306 general physicsAxionPhysical Review D
researchProduct

New methods of delivery of amphotericin B.

1993

Fungal infections continue to be a major problem in the management of immunocompromised patients. Despite its formidable toxicity and treatment failures, amphotericin B is still the drug of choice for most of these infections. One strategy for reducing the toxicity of amphotericin B and thus permitting administration of higher doses is that of using less toxic formulations. Entrapping amphotericin B into liposomes or binding it to other substances reduces its toxicity to host cells, whereas the selective binding of amphotericin B to ergosterol preserves its toxicity to fungal cells. Adding fungus-specific antibodies to such liposomes may further increase the efficiency of drug targeting. Th…

Microbiology (medical)DrugTime Factorsmedia_common.quotation_subjectPharmacologyAspergillosisRoute of administrationImmunocompromised HostAmphotericin BAmphotericin BMedicineAnimalsAspergillosisHumansAdministration Intranasalmedia_commonAerosolsDosage Formsbusiness.industrymedicine.diseaseClinical trialInfectious DiseasesTargeted drug deliveryMycosesToxicityNasal administrationbusinessmedicine.drugClinical infectious diseases : an official publication of the Infectious Diseases Society of America
researchProduct

Leptonic universality breaking in Upsilon decays as a probe of new physics

2003

In this work we examine the possible existence of new physics beyond the standard model which could modify the branching fractions of the leptonic (mainly tauonic) decays of bottomonium vector resonances below the $B\bar{B}$ threshold. The decay width is factorized as the product of two pieces: a) the probability of an intermediate pseudoscalar color-singlet $b\bar{b}$ state (coupling to the dominant Fock state of the Upsilon via a magnetic dipole transition) and a soft (undetected) photon; b) the annihilation width of the $b\bar{b}$ pair into two leptons, mediated by a non-standard CP-odd Higgs boson of mass about 10 GeV, introducing a quadratic dependence on the lepton mass in the partial…

PhysicsNuclear and High Energy PhysicsParticle physicsPhotonAnnihilationMagnetic dipole transitionPhysics beyond the Standard ModelHigh Energy Physics::PhenomenologyFísicaFOS: Physical sciencesAstronomy and AstrophysicsAtomic and Molecular Physics and OpticsPseudoscalarHigh Energy Physics - PhenomenologyFock stateHigh Energy Physics - Phenomenology (hep-ph)Higgs bosonHigh Energy Physics::ExperimentLepton
researchProduct